BIO-RAD LABORATORIES-A (BIO) Stock Fundamental Analysis
NYSE:BIO - New York Stock Exchange, Inc. - US0905722072 - Common Stock - Currency: USD
BIO gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 55 industry peers in the Life Sciences Tools & Services industry. BIO has an excellent financial health rating, but there are some minor concerns on its profitability. BIO does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year BIO was profitable.
In the past year BIO had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: BIO reported negative net income in multiple years.
BIO had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
BIO has a Return On Assets of -22.71%. This is in the lower half of the industry: BIO underperforms 65.45% of its industry peers.
With a Return On Equity value of -32.40%, BIO is not doing good in the industry: 60.00% of the companies in the same industry are doing better.
With a decent Return On Invested Capital value of 2.70%, BIO is doing good in the industry, outperforming 61.82% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for BIO is significantly below the industry average of 13.60%.
The 3 year average ROIC (2.69%) for BIO is below the current ROIC(2.70%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -22.71% | ||
| ROE | -32.4% | ||
| ROIC | 2.7% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
1.3 Margins
BIO has a Operating Margin of 12.14%. This is in the better half of the industry: BIO outperforms 69.09% of its industry peers.
In the last couple of years the Operating Margin of BIO has remained more or less at the same level.
The Gross Margin of BIO (53.68%) is better than 61.82% of its industry peers.
BIO's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.14% | ||
| PM (TTM) | N/A | ||
| GM | 53.68% |
OM growth 3Y-15.52%
OM growth 5Y1.14%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BIO is destroying value.
Compared to 1 year ago, BIO has less shares outstanding
The number of shares outstanding for BIO has been reduced compared to 5 years ago.
BIO has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 3.23 indicates that BIO is not in any danger for bankruptcy at the moment.
BIO's Altman-Z score of 3.23 is fine compared to the rest of the industry. BIO outperforms 67.27% of its industry peers.
BIO has a debt to FCF ratio of 3.62. This is a good value and a sign of high solvency as BIO would need 3.62 years to pay back of all of its debts.
With a decent Debt to FCF ratio value of 3.62, BIO is doing good in the industry, outperforming 72.73% of the companies in the same industry.
A Debt/Equity ratio of 0.18 indicates that BIO is not too dependend on debt financing.
BIO's Debt to Equity ratio of 0.18 is in line compared to the rest of the industry. BIO outperforms 58.18% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.62 | ||
| Altman-Z | 3.23 |
ROIC/WACC0.28
WACC9.75%
2.3 Liquidity
A Current Ratio of 5.99 indicates that BIO has no problem at all paying its short term obligations.
BIO has a better Current ratio (5.99) than 81.82% of its industry peers.
A Quick Ratio of 4.43 indicates that BIO has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 4.43, BIO is in the better half of the industry, outperforming 70.91% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.99 | ||
| Quick Ratio | 4.43 |
3. Growth
3.1 Past
The earnings per share for BIO have decreased by -1.49% in the last year.
Measured over the past 5 years, BIO shows a small growth in Earnings Per Share. The EPS has been growing by 7.84% on average per year.
The Revenue has decreased by -2.46% in the past year.
BIO shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.11% yearly.
EPS 1Y (TTM)-1.49%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%10.92%
Revenue 1Y (TTM)-2.46%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%-4.16%
3.2 Future
Based on estimates for the next years, BIO will show a decrease in Earnings Per Share. The EPS will decrease by -4.33% on average per year.
The Revenue is expected to grow by 1.35% on average over the next years.
EPS Next Y-16.18%
EPS Next 2Y-3.39%
EPS Next 3Y2.4%
EPS Next 5Y-4.33%
Revenue Next Year-2.19%
Revenue Next 2Y0.61%
Revenue Next 3Y1.79%
Revenue Next 5Y1.35%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 22.85, which indicates a rather expensive current valuation of BIO.
BIO's Price/Earnings ratio is a bit cheaper when compared to the industry. BIO is cheaper than 76.36% of the companies in the same industry.
BIO's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 27.15.
A Price/Forward Earnings ratio of 25.08 indicates a quite expensive valuation of BIO.
BIO's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. BIO is cheaper than 69.09% of the companies in the same industry.
BIO is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 21.60, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.85 | ||
| Fwd PE | 25.08 |
4.2 Price Multiples
83.64% of the companies in the same industry are more expensive than BIO, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 20.36 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)2.92
EPS Next 2Y-3.39%
EPS Next 3Y2.4%
5. Dividend
5.1 Amount
BIO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
241.32
-2.66 (-1.09%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners89.78%
Inst Owner Change-1.39%
Ins Owners3.67%
Ins Owner Change0%
Market Cap6.76B
Analysts76.36
Price Target321.64 (33.28%)
Short Float %6.32%
Short Ratio3.21
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.53%
Min EPS beat(2)0.1%
Max EPS beat(2)38.97%
EPS beat(4)4
Avg EPS beat(4)40.99%
Min EPS beat(4)0.1%
Max EPS beat(4)72.05%
EPS beat(8)7
Avg EPS beat(8)21.55%
EPS beat(12)8
Avg EPS beat(12)14.41%
EPS beat(16)12
Avg EPS beat(16)19.4%
Revenue beat(2)1
Avg Revenue beat(2)-0.8%
Min Revenue beat(2)-2.71%
Max Revenue beat(2)1.11%
Revenue beat(4)2
Avg Revenue beat(4)-0.33%
Min Revenue beat(4)-2.71%
Max Revenue beat(4)2.41%
Revenue beat(8)2
Avg Revenue beat(8)-2.22%
Revenue beat(12)3
Avg Revenue beat(12)-1.99%
Revenue beat(16)6
Avg Revenue beat(16)0.12%
PT rev (1m)-3.57%
PT rev (3m)-14.66%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-28.41%
EPS NY rev (1m)-0.68%
EPS NY rev (3m)-11.47%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.18%
Revenue NY rev (1m)-0.08%
Revenue NY rev (3m)-1.85%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.85 | ||
| Fwd PE | 25.08 | ||
| P/S | 2.66 | ||
| P/FCF | 20.36 | ||
| P/OCF | 13.12 | ||
| P/B | 1.01 | ||
| P/tB | 1.13 | ||
| EV/EBITDA | N/A |
EPS(TTM)10.56
EY4.38%
EPS(NY)9.62
Fwd EY3.99%
FCF(TTM)11.85
FCFY4.91%
OCF(TTM)18.39
OCFY7.62%
SpS90.72
BVpS238.45
TBVpS213.07
PEG (NY)N/A
PEG (5Y)2.92
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -22.71% | ||
| ROE | -32.4% | ||
| ROCE | 3.42% | ||
| ROIC | 2.7% | ||
| ROICexc | 3.31% | ||
| ROICexgc | 3.67% | ||
| OM | 12.14% | ||
| PM (TTM) | N/A | ||
| GM | 53.68% | ||
| FCFM | 13.07% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
ROICexc(3y)3.19%
ROICexc(5y)3.05%
ROICexgc(3y)3.46%
ROICexgc(5y)3.26%
ROCE(3y)3.41%
ROCE(5y)3.39%
ROICexcg growth 3Y8.28%
ROICexcg growth 5Y0.09%
ROICexc growth 3Y5.96%
ROICexc growth 5Y-0.55%
OM growth 3Y-15.52%
OM growth 5Y1.14%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
F-Score5
Asset Turnover0.27
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.62 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 7.2% | ||
| Interest Coverage | -6.57 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.99 | ||
| Quick Ratio | 4.43 | ||
| Altman-Z | 3.23 |
F-Score5
WACC9.75%
ROIC/WACC0.28
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)5.76%
Cap/Sales(5y)5.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.49%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%10.92%
EPS Next Y-16.18%
EPS Next 2Y-3.39%
EPS Next 3Y2.4%
EPS Next 5Y-4.33%
Revenue 1Y (TTM)-2.46%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%-4.16%
Revenue Next Year-2.19%
Revenue Next 2Y0.61%
Revenue Next 3Y1.79%
Revenue Next 5Y1.35%
EBIT growth 1Y-9.77%
EBIT growth 3Y-19.1%
EBIT growth 5Y3.28%
EBIT Next Year22.43%
EBIT Next 3Y13.71%
EBIT Next 5Y6.41%
FCF growth 1Y162.24%
FCF growth 3Y-20.82%
FCF growth 5Y-5.84%
OCF growth 1Y112.81%
OCF growth 3Y-12.08%
OCF growth 5Y-0.13%